Danish drug manufacturer Novo Nordisk's top product Ozempic - a glucagon-like peptide 1 - generated some *** billion kroner in sales in 2024. Another GLP-1 product, Rybelsus, was the company's third best-selling product.

Net sales per quarter of Danish pharmaceutical company Novo Nordisk increased almost constantly in the provided period. The fourth quarter of 2024 set another record high, reaching nearly 86 billion Danish kroner. This statistic shows Novo Nordisk's net sales per quarter between 2021 and 2024. Shift change at big pharma's topNovo Nordisk has been in the public's focus lately, mostly due to its diabetes and weight loss drug Ozempic/Wegovy. As a result, Novo Nordisk's share prices have increased massively, making it the world's third ranked pharmaceutical company based on market capitalization, topped only by Eli Lilly and Johnson & Johnson (which is not a pure play pharma company). As of September 2024, Novo Nordisk was valued at over 440 billion U.S. dollars, while Eli Lilly stood at almost half a trillion U.S. dollars. Is 'semaglutide' the new superstar?Novo Nordisk's highly valued products Ozempic, Rybelsus, and Wegovy are all based on semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Ozempic was approved in June 2017 in the U.S., as an injectable antidiabetic medication. In September 2019, a version for oral administration (Rybelsus) was approved. Finally, a high dosage version of the drug (Wegovy) was approved in June 2021, marketed as a weight loss/anti-obesity medication. Since overweight and obesity are huge problems in many (developed) countries, this product is believed to have very high market potential in the near future.

Net sales of Danish pharmaceutical company Novo Nordisk increased annually until 2016, when it reached around 111.8 billion Danish kroner, and then stagnated in 2017. In the period 2018-2024, net sales increased again, and reached a peak at over 290 billion Danish kroner in 2024.

Danish drug manufacturer Novo Nordisk's diabetes subsegment of glucagon-like peptide 1 (GLP-1) products generated nearly 150 billion kroner in 2024. The company's total insulin-related sales stood at some 55 billion kroner, of which fast-acting insulins formed the largest single share.

In 2024, Danish biopharma company Novo Nordisk generated 99.2 of its total sales outside its home country. This statistic shows the share of sales outside of Denmark of Novo Nordisk from 2007 to 2024. Novo Nordisk is a Danish pharmaceutical company founded in 1923. The company's key product is diabetes medication, but does also produce pharmaceuticals for other use. The share of sales to outside Denmark was almost 100 percent for the whole period.

Johnson and Johnson is a leading international pharmaceutical company. In 2024, among its top pharmaceutical products was Darzalex which earned some 11.7 billion U.S. dollars of revenue. Darzalex is a drug used in the treatment of multiple myeloma and light chain amyloidosis. International pharmaceutical companies There are several major pharmaceutical companies that are making significant economic impacts globally. In 2023, Johnson & Johnson, AbbVie, and Novartis were the top pharmaceutical companies based on their prescription drug sales globally. When viewed by market capitalization, Johnson and Johnson was the third ranked global pharmaceutical company, as of 2024. Top pharmaceuticals The global pharmaceutical industry showed significant growth of revenues over the past two decades. Globally, oncology, diabetes and immunology are considered the top therapeutic areas for future growth. In 2023, when covid vaccines are excluded, Humira by AbbVie, Keytruda by Merck & Co. and Ozempic by Novo Nordisk were the top drugs based on sales worldwide.

Danish biopharmaceutical company Novo Nordisk generated ** percent of its total sales in 2024 in the North American region. That was a *** percent increase compared to the year before.

product market has been steadily increasing over recent years, and forecasts suggest a substantial growth trajectory in the upcoming period.

This statistic shows the 2024 ranking of the top 10 biotech and pharmaceutical companies worldwide, based on net income. U.S.-based company Johnson & Johnson was ranked first with a net income of 16.4 billion U.S. dollars. Biotech and pharmaceutical companiesJohnson & Johnson and Merck & Co., both based in the United States, are among the world’s largest biotechnology and pharmaceutical companies based on their net incomes of approximately 16.4 billion U.S. dollars and 13.7 billion U.S. dollars, respectively, as of 2024. Johnson & Johnson generated some 86 billion U.S. dollars of revenue in 2023. Pfizer had record-high annual revenues during the COVID-19 vaccination campaign, reaching 100 billion U.S. dollars in 2022.

Story of a former blockbuster Lyrica was once one of Pfizer’s most successful products. It is an anticonvulsant for neuropathic pain and is also used as therapy for partial seizures. In the EU and in Russia, Lyrica has also been approved to treat general anxiety disorder. In 2017, this prescription medication generated some five billion U.S. dollars in revenue.

Product Market size is rising upward in the past few years And it is estimated that the market will grow significantly in the forecasted period

product market has been steadily increasing over recent years, and forecasts suggest a substantial growth trajectory in the upcoming period.

• The global industry was valued at US$ 1.1 Bn in 2023
• It is expected to grow at a CAGR of 5.2% from 2024 to 2034 and reach US$ 2.0 Bn by the end of 2034

Hypersensitivity Pneumonitis Market Overview

Regional Analysis of the Hypersensitivity Pneumonitis Market

Global Hypersensitivity Pneumonitis Market Snapshot

Explosive growth in biotechnology in recent years can't be understated. What's fueling this rapid growth varies, as biotech's applications range from healthcare and agriculture to energy. COVID-19 brought more attention to biotechnology, as biotech companies were central to vaccine development and reopening the economy. Biotech's potential to develop vaccines shifted the industry's trajectory, with investment reaching unprecedented levels globally and spurring more start-up activity than ever. Sky-high investment began settling in 2022 as higher interest rates moved risk-averse investors away from the industry. While investor uncertainty is alleviating in 2024, many biotechnology companies will still navigate a challenging funding environment. Globally, rising government investment toward biotechnology, specifically regarding R&D, expedited pathways and innovative therapies, helps offset this impact. In all, revenue has been expanding at a CAGR of 2.4% to an estimated $558.8 billion over the past five years, including expected growth of 2.4% in 2023. Research and development (R&D) is critical for biotechnology companies to successfully discover, develop and commercialize new products. Yet, early-stage biotech can't cover the skyrocketing costs of R&D, relying on outside funding for growth instead. Biotech evaded the economic downturn during COVID-19 as investors poured capital into the field, but investment settled as the pandemic went on the back burner in 2022. While interest rate hikes are settling in influential markets like the US in 2024, economic headwinds in nations like China, regulatory pressures and geopolitical tensions foster an uncertain funding environment. Where the biotechnology industry is headed globally will depend on several factors. Biotechnology's potential to slow climate change, accelerate the energy transition and transform healthcare delivery will encourage more government support nationally, regionally and internationally. Developing a robust bioeconomy will also be a central goal of many developed economies, especially as other countries build momentum. Merger and acquisition activity will accelerate as giant multinational pharma companies lose patents to their blockbuster drugs and acquire promising biotechs to augment their pipelines. Industry-wide revenue will continue expanding, rising at a CAGR of 3.4% to an estimated $659.9 billion over the next five years.

• The global industry was valued at US$ 27.7 Bn in 2023
• It is expected to grow at a CAGR of 5.6% from 2024 to 2034 and reach US$ 50.3 Bn by the end of 2034

Lactose Intolerance Market Overview

Regional Analysis of Lactose Intolerance Treatment Industry

Lactose Intolerance Treatment Market Snapshot